GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Inhibikase Therapeutics, Inc. ( ($IKT) ) has released its Q2 earnings. Here is a breakdown of the information Inhibikase Therapeutics, Inc.

Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - ...

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.